Nephrologist Ravi Thadhani Named Cedars-Sinai’s First Chief Physician Executive
India-West News Desk
LOS ANGELES, CA – Cedars-Sinai has appointed Dr. Ravi Thadhani as its first executive vice president, chief physician executive and dean of the Medical Faculty, elevating an Indian American physician-scientist with decades of experience in academic medicine, clinical leadership and medical research to one of the institution’s top leadership roles.
Thadhani will assume the newly created position on September 1, overseeing Cedars-Sinai’s clinical operations, academic programs and research initiatives. He currently serves as executive vice president of Clinical Affairs and chief medical officer for Cedars-Sinai Medical Center and Cedars-Sinai Health System.
In his expanded role, Thadhani will continue to lead efforts related to clinical quality, patient safety, medical affairs and standards of care while also overseeing Cedars-Sinai Health Sciences University, the Burns and Allen Research Institute and other academic programs.
Cedars-Sinai President and CEO Dr. Peter L. Slavin said Thadhani brings, “a rare combination of academic excellence, clinical leadership and scientific innovation.”
Thadhani’s career has spanned some of the nation’s leading medical institutions. Before returning to Cedars-Sinai, he served as executive vice president for health affairs at Emory University, vice chair of the Emory Healthcare Board of Directors and executive director of the Woodruff Health Sciences Center.
Earlier, he held leadership positions at Massachusetts General Hospital and Harvard Medical School. He first joined Cedars-Sinai in 2017 as vice dean for Research and Education, serving until 2019, before returning to Harvard, where he was professor of medicine and later served as chief academic officer and dean for Faculty Affairs at Mass General Brigham and Harvard Medical School.
A specialist in nephrology, Thadhani has built an international reputation through his research on kidney disease and pregnancy-related complications. He has authored or co-authored more than 300 scientific papers published in journals including The New England Journal of Medicine, The Lancet and the Journal of the American Medical Association.
His research on preeclampsia, a potentially serious pregnancy complication, led to collaboration with Cedars-Sinai researchers in developing the first U.S. Food and Drug Administration-approved test to predict the condition.
Thadhani has also received recognition from the nation’s leading scientific organizations. Earlier this year, he was elected a Fellow of the American Association for the Advancement of Science, following his election to the National Academy of Medicine in 2025.
